D-0381-2021 Class II Ongoing
FDA drug recall D-0381-2021 was initiated by Hyobin LLC on Apr 6, 2021 and is designated Class II. Reason for recall: Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil. The recall status is ongoing. Affected quantity: 500 cards.
Recall details
- Product Type
- Drugs
- Report Date
- May 26, 2021
- Initiation Date
- Apr 6, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 500 cards
Product description
PremierZen Extreme 3000, packaged in cardboard blisters containing one capsule per card, Distributed by Yolo Studio, Cliffside Park, NJ
Reason for recall
Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil.
Distribution pattern
USA Nationwide
Code information
all lots
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0381-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026